You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses

    SBC: HAWAII BIOTECH, INC.            Topic: R

    DESCRIPTION provided by applicant The tick borne flavivirus TBFV group includes a number of important human pathogens that result in serious encephalitic or hemorrhagic diseases that are either Category B or C priority pathogens The TBFV are considered to be emerging or re emerging pathogens due to increases in the number of human cases the expansion of geographic distribution and emergen ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE

    SBC: SIBTECH, INC.            Topic: NCI

    The overall goal of this collaborative project between SibTech Inc PI Backer J and Johns Hopkins University PI Pomper M is clinical development of efficient and cost effective anti angiogenic Lu radiopharmaceutical scV Lu for VEGF receptor mediated targeting of angiogenic tumor vasculature Current very expensive anti angiogenic compounds induce transient regression of tumor vascula ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE

    SBC: Recombinant Technologies LLC            Topic: NIA

    DESCRIPTIONprovided by applicantAlzheimer s diseaseADrepresents a progressive degenerative illness that affects the brainresulting in memory impairmentThe complex etiology of AD is not fully resolvedalthough toxic isoforms of amyloidAplaques are strongly implicatedCurrent treatment options are considered to be symptomaticThey are only moderately effective in stabilizing or improving cognitive and ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Antifungal therapy against drug resistant fungal pathogens.

    SBC: LIFEPHARMS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Despite medical advances fungal infections still exact a heavy burden on the HIV AIDs population AIDs related fungal infections account for of all AIDs related deaths In the developed world AIDS related fungal infections are most frequently associated with Candida albicans but Aspergillus fumigatus and Cryptococcus neoformans are also common Unfortunat ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder

    SBC: Biomedical Development Corporation            Topic: 103

    DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. A New Technique for Diabetic Foot Ulcers

    SBC: Noveratech L.L.C.            Topic: 200

    ABSTRACT Diabetes is the leading cause of nontraumatic lower extremity amputations in the United States Diabetic foot ulcers DFUs are responsible for more hospitalizations than any other diabetic complications Currently even the best available treatments achieve only a healing rate for these wounds and this healing is often only temporary with a chance of recurring Our company has ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Precision Betamethasone Microspheres for Transtympanic Delivery & SSNHL Treatment

    SBC: ORBIS BIOSCIENCES, INC.            Topic: NIDCD

    DESCRIPTION provided by applicant New treatment options are needed for inner ear disorders including Meniereandapos s disease sensorineural hearing loss autoimmune inner ear disease and tinnitus In the absence of FDA approved drugs physicians use improvised treatments including the administration of off label steroids which lack safety and efficacy data These ad hoc approaches often fail ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAMS

    Abstract The long term product goal of this project is a small molecule rheumatoid arthritis RA therapeutic which acts by reducing the inflammatory response triggered by the pro inflammatory cytokine macrophage migration inhibitory factor MIF The therapeutic benefit of MIF inhibition in RA disease models has been well established by small molecules that bind to a catalytic site of the MIF tri ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical development of 18F PET tracer for imaging VEGF receptors

    SBC: SIBTECH, INC.            Topic: 102

    DESCRIPTION provided by applicant The overall goal of this collaborative Fast Track project is clinical development of a novel F PET tracer for molecular imaging of receptors for vascular endothelial growth factor VEGFR This receptor is the major anti angiogenic drug target in oncology patients Critically VEGFR prevalence decreases when VEGF VEGFR anti angiogenic inhibitors andquot worka ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease

    SBC: ENDOPROTECH, INC.            Topic: 150

    DESCRIPTION provided by applicant Alcoholic Liver Disease ALD remains a leading cause of death from liver disease in the U S and no FDA approved therapy exists Abnormal cytokine metabolism is a major feature of ALD Elevated serum concentrations of tumor necrosis factor TNF and TNF inducible proinflammatory cytokines chemokines such as IL and IL have been reported in patients w ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government